Thanks for the opportunity. While our EBITDA margin has seen improvement on Y-o-Y basis, also on versus Q2, but the gross margin has seen some softness. What could be the reason for that?
And also, in CDMO, if you look at 9 months growth of 18%, can you at least give some color in terms of how is it going to growth in the API business, generic API business?
First on the -- what was the growth for trade generics in the quarter?
Okay. And in terms of the additional cost you mentioned because of the new initiative, can you quantify what could be the cost? And will it be starting from Q2, or it will be more back-ended?
Yes, my question was you're talking about doubling of the revenue in next five years. So what kind of investment are you looking in terms of capex to have that kind of a revenue?
Okay. And secondly, in terms of new RFQ what you are getting, is it for the existing chemistry of Suven or this is new chemistry maybe of Cohance and how we are looking at in terms of chemistry - wise new molecules what you are developing?
The outlook for second-half and '25 looks positive. So, will it be driven by more of the animal health project or the current commercialized molecule has the scope to drive it further, is there any large molecule or the molecule where there's a large opportunity in the current commercialized molecule as well?
On synthesis side, will it be the animal health project only or the current commercial molecules also should the ARV growth as well?
The outlook for second-half and '25 looks positive. So, will it be driven by more of the animal health project or the current commercialized molecule has the scope to drive it further, is there any large molecule or the molecule where there's a large opportunity in the current commercialized molecule as well?
On synthesis side, will it be the animal health project only or the current commercial molecules also should the ARV growth as well?